腹腔镜与开腹二期肝切除治疗双叶结直肠癌肝转移的倾向评分匹配研究
该研究回顾性分析2007至2017年两家三级中心86例接受完整二期肝切除的双叶结直肠癌肝转移患者,比较腹腔镜与开腹二期肝切除的短期和长期结局。经倾向评分匹配后各25例,腹腔镜组在第二期手术中出血更少、并发症更少、住院更短且化疗更早开始,远期生存与复发模式相当。
要点
- 腹腔镜二期肝切除治疗双叶结直肠癌肝转移安全可行,短期结局优于开腹。
- 匹配后第二期腹腔镜组并发症32% vs 60%、住院9 vs 16天、化疗1.6 vs 2个月。
- 两组3年总生存、无复发生存及肝无复发生存差异无统计学意义。
核心结论
- 对于双叶结直肠癌肝转移,腹腔镜二期肝切除与开腹相比安全可行,手术与肿瘤学结局有利。
研究设计与样本
- 回顾性队列研究,纳入2007至2017年两家三级中心86例连续接受完整二期肝切除(第一期左肝清除,第二期标准/扩大右肝切除)的双叶结直肠癌肝转移患者。
- 比较腹腔镜与开腹二期肝切除的短期和长期结局,并行倾向评分匹配前后分析;匹配后腹腔镜25例、开腹25例。
主要发现
- 第一期手术:腹腔镜组住院时间4 vs 7.5天,P < .001。
- 第二期手术:腹腔镜组出血量250 vs 500 mL(P = .040),术后并发症32% vs 60%(P = .047),住院9 vs 16天(P = .013),化疗开始时间1.6 vs 2个月(P = .039)。
- 远期结局:3年总生存80% vs 54%(P = .154),2年无复发生存20% vs 18%(P = .200),2年肝无复发生存39% vs 33%(P = .269)。
- 两组复发模式相当,但腹腔镜组针对复发再次肝切除更常见(56% vs 0%;P = .006)。
临床怎么用
- 在适宜的双叶结直肠癌肝转移患者中,腹腔镜二期肝切除可作为开腹手术的可行选择,可能缩短住院并减少第二期手术并发症。
- 腹腔镜组化疗开始更早,且复发后再次肝切除比例更高,提示其可能有利于后续治疗衔接。
局限性
- 回顾性研究,样本量较小(匹配后每组25例),来自两家三级中心,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The safety and feasibility of laparoscopic, two-stage hepatectomy for bilobar colorectal liver metastases is poorly evaluated. METHODS: We reviewed retrospectively 86 consecutive patients who underwent complete two-stage hepatectomy (left lobe clearance as the first stage and standard/extended right hepatectomy as the second stage) for bilobar colorectal liver metastases between 2007 and 2017 in 2 tertiary centers. Short- and long-term outcomes were compared between laparoscopic and open two-stage hepatectomy before and after propensity score matching. RESULTS: Laparoscopic two-stage hepatectomy was performed in 38 patients and open two-stage hepatectomy in 48. After propensity score matching, 25 laparoscopic and 25 open patients showed similar preoperative characteristics. For the first stage, a laparoscopic approach was associated with lesser hospital stays (4 vs 7.5 days; P < .001). For the second stage, a laparoscopic approach was associated with less blood loss (250 vs 500 mL; P = .040), less postoperative complications (32% vs 60%; P = .047), lesser hospital stays (9 vs 16 days; P = .013), and earlier administration of chemotherapy (1.6 vs 2 months; P = .039). Overall survival, recurrence-free survival, and liver-recurrence-free survival were comparable between the groups (3-year overall survival: 80% vs 54%; P = .154; 2-year recurrence-free survival: 20% vs 18%; P = .200; 2-year liver-recurrence-free survival: 39% vs 33%; P = .269). Although both groups had comparable recurrence patterns, repeat hepatectomies for recurrence were performed more frequently in the laparoscopic two-stage hepatectomy group (56% vs 0%; P = .006). CONCLUSION: Laparoscopic two-stage hepatectomy for bilobar colorectal liver metastases is safe and feasible with favorable surgical and oncologic outcomes compared to open two-stage hepatectomy.
引用
- Okumura S, Goumard C, Gayet B, et al. Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study. Surgery. 2019. PMID: 31395397. doi:10.1016/j.surg.2019.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。